Filing summary
Issuer and period: The supplied filing is for Organovo Holdings, Inc. (Nasdaq: ONVO), not Vivosim Labs, Inc. It is a Form 10-Q for the fiscal quarter ended December 31, 2020, filed February 8, 2021. The filing describes this as the third quarter of fiscal 2021; the requested “2020 Q3” period does not match the filing period.
Business context and results
Organovo is an early-stage biotechnology company developing 3D human tissues and disease models for drug discovery. After suspending its liver-therapy and other internal pipeline programs in 2019 and exploring strategic alternatives, it recommenced research and development during the quarter, shifting its focus toward identifying and developing drug candidates. It reported no revenue in either the quarter or nine-month period.
| Metric | Three months ended Dec. 31, 2020 | Three months ended Dec. 31, 2019 | Nine months ended Dec. 31, 2020 | Nine months ended Dec. 31, 2019 |
|---|---|---|---|---|
| Revenue | $0 | $0.298 million | $0 | $2.196 million |
| Operating loss | $2.492 million | $5.234 million | $14.228 million | $18.582 million |
| Net loss | $2.511 million | $3.370 million | $14.230 million | $15.987 million |
| Net loss per share, basic and diluted | $0.37 | $0.60 | $2.14 | $2.40 |
| Operating cash used | Not provided for the quarter | Not provided for the quarter | $11.209 million | $11.673 million |
Margins are not meaningful because revenue was zero in 2020. For the nine-month period, lower research and development and general and administrative costs helped reduce operating losses, but the company remained loss-making. Quarterly R&D expense rose to $0.402 million from $0.145 million as activities resumed. Quarterly SG&A declined to $2.090 million from $5.374 million, partly because the prior-year quarter included merger-related costs, leasehold write-offs and severance. The 2020 nine-month SG&A total included $5.218 million of stock-based compensation; the filing cites accelerated equity vesting associated with a change of control.
Financial position, liquidity and financing
- At December 31, 2020, cash and cash equivalents were $18.836 million, with an additional $0.111 million of restricted cash. Cash and cash equivalents were $27.356 million at March 31, 2020.
- Working capital was $19.3 million, down from $26.5 million at March 31, 2020. Current liabilities were $0.829 million; the filing reports no debt balance.
- Nine-month cash used in operations was $11.209 million; investing activities used $0.282 million; financing activities provided $3.082 million, primarily from stock issuance. Cash, cash equivalents and restricted cash decreased by $8.409 million over the period.
- The company issued 379,655 shares through its at-the-market facility for approximately $3.0 million net proceeds. Shares outstanding were 7,117,083 at December 31, 2020.
- Management said available cash should cover obligations for at least the next 12 months, but also said additional capital is needed to implement the renewed business plan. A $150 million shelf registration became effective January 29, 2021, including up to $50 million available through the ATM program; this is financing capacity, not committed funding.
Material changes, outlook and risks
- Strategic and governance reset: Following the failed proposed merger with Tarveda, a cooperation agreement and September 2020 annual meeting led to a new director slate and the restart of operations. The company’s goal is to establish a drug-candidate pipeline and begin human clinical testing for at least one candidate within three to five years; this is an aim, not a firm forecast.
- One-time costs and dilution: The board changes triggered approximately $2.8 million in severance charges, of which about $2.669 million had been paid by December 31, 2020. The company also reported substantial one-time D&O insurance costs. The August 2020 1-for-20 reverse stock split restored Nasdaq bid-price compliance, but continued listing is not assured. Equity awards and future fundraising may dilute shareholders.
- Capital and execution risks: The company expects additional operating losses as R&D increases and does not expect meaningful revenue in the foreseeable future. Its renewed business strategy is unproven; it has not identified drug candidates under this model. Success depends on technical progress, access to human cells, hiring, partnerships, regulatory development and future financing. Financing may be unavailable or dilutive, and failure to raise funds could materially harm operations and going-concern prospects.
- COVID-19: Management said operations had not otherwise been negatively affected at the time, but warned that the pandemic could disrupt research, supply chains, partners’ clinical activities and access to capital.
- Related parties: Keith Murphy, the executive chairman and principal executive officer, and other personnel have ties to Viscient Biosciences. The companies entered into an agreement involving services, shared facilities and equipment; Organovo reported approximately $27,000 in consulting expense from Viscient and purchased lab equipment for approximately $35,000 during the quarter. Conflicts over time, business opportunities and intellectual property are disclosed risks.
- Legal and controls: The SEC informed Organovo in October 2020 that it had concluded its investigation and did not intend to recommend an enforcement action based on information then available. The company reported no accrued loss contingencies and said disclosure controls were effective; it identified no material change in internal control during the quarter.
Important facts for investors to verify
- Confirm the issuer and reporting period: this filing is Organovo Holdings’ quarter ended December 31, 2020, not a Vivosim Labs filing.
- Track cash burn, hiring and R&D spending against management’s stated minimum 12-month liquidity expectation and the need for additional capital.
- Check whether the 3D-tissue drug-discovery strategy produces candidates, partnerships or progress toward the stated three-to-five-year clinical-testing goal.
- Review future ATM or other shelf offerings, potential dilution, share-count changes and continued Nasdaq listing compliance.
- Monitor related-party transactions and safeguards governing shared personnel, facilities, services and intellectual property with Viscient.